pfizer - Search News

Head of Pfizer booed by Trump supporters

Newsweek on MSN · 8h

Trump Introducing Pfizer CEO Sparks Loud Booing Inside White House

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of January 2025.

Hosted on MSN · 22h

Video: Head of Pfizer booed by Trump supporters

Head of Pfizer booed by Trump supporters At a Black History Month reception in Washington, DC, Trump shouted out the head of Pfizer, Albert Bourla, who was met with relentless booing. #news #trump #pfizer #politics #blackhistorymonth #washingtondc Daily Mail Website: Daily Mail Facebook: Daily Mail IG: Daily Mail

Irish Star on MSN · 23h

Trump giggles as White House crowd brutally boos head of Pfizer being introduced

"We're also have the head of Pfizer here. One of the great businessmen," Trump said. The raucous boos that followed rattled the president, who giggled, then continued going around

Pfizer, Haemophilia B and gene therapy

Hosted on MSN · 9h

Pfizer stops commercialization of hemophilia gene therapy Beqvez

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez is a one-time therapy that was approved in the U.

FiercePharma · 6h

Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez.

YAHOO!Finance · 3h

Pfizer shelves haemophilia gene therapy Beqvez amid low demand

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A Pfizer spokesperson told Pharmaceutical Technology in a statement that the decision,

An awkward moment for Pfizer’s Bourla in Washington

The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...

5h

Pfizer: Investors Won't Stick Around Forever

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

BioPharma Dive4h

Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

Pharmalittle: We’re reading about RFK Jr. targeting CDC and FDA advisers, a Pfizer gene therapy, and more

HHS Secretary Robert F. Kennedy Jr. is preparing to remove committee members who advise the government on vaccine approvals ...

2d

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

3d

3 Things You Need to Know If You Buy Pfizer Today

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

2don MSN

Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...

2d

Pfizer Stock's Upside Got Bigger

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results